PDCD1 and hepatocellular carcinoma: Decrease in PD-1 expression on T cells has been reported to be associated with improved HCC prognosis in patients following sorafenib treatment, prior anti-PD-1 antibody treatment can amplify HCC response to sorafenib therapy (37, 38).